Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.
Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.
We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.
In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months. Request Insights
IN THE NEWSJanuary 7, 2020: AI Therapeutics, a clinical-stage biopharmaceutical company, announced substantial progress on two of their programs - LAM-001, world’s first inhaled formulation of rapamycin that would be studied in clinical trials and LAM-004, which has finished a Phase 1 trial in patients having facial angiofibroma.
January 16, 2020: AI Therapeutics announced that their LAM-002 has received Fast Track status and Orphan Drug Designation from the U.S. FDA for Pivotal Trial Design of the treatment of follicular lymphoma.
Lymphangioleiomyomatosis (LAM) is a lethargic, progressive growth of smooth muscle cells all through the lungs, pulmonary blood vessels, lymphatics, and pleurae, leading to alteration of lung architecture, cystic emphysema, and progressive worsening of lung function. LAM is predominant in women, usually affecting those between 20 and 40 years. It is caused by mutations in the TSC1 or TSC2 genes, that are vital for the production of a protein known as hamartin and tuberin, responsible for destroying the tumors by preventing cells from growing and dividing in an uncontrolled way. Diagnosis is suspected based on symptoms and chest x-ray results and is confirmed by high-resolution CT, but the illness is slowly progressive and might often lead to respiratory failure and death in the future. Treatment might include consuming sirolimus or lung transplantation.
The lymphangioleiomyomatosis market is expected to observe a substantial CAGR during the forecast period, i.e., 2020-2028. The market is segmented by type, therapy type, treatment, drugs, route of administration, end-users, distribution channel, and region. Among distribution channel segmentation, the hospital pharmacies segment is anticipated to grow significantly during the forecast period on account of growing numbers for registered lung disease patients worldwide, rising awareness for chronic lung diseases, and R&D initiatives resulting in advanced medications and drugs to cure the illness.
An increase in the occurrence of target diseases and a rise in the number of lifestyle-related disorders are the key factors that are driving the growth of the global lymphangioleiomyomatosis market.
Furthermore, initiatives taken by numerous government and private organizations to spread alertness for the disease, rise in disposable income and surge in healthcare facilities in developing nations, novel R&D initiatives to produce medications, technological advancements, and investments by major players are estimated to drive the market growth in the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
Stringent government regulations in certain nations, lack of awareness, slow detection of the disease, and high costs involved in the treatments might also contribute as the growth constraints for the overall lymphangioleiomyomatosis market.
Our in-depth analysis of the lymphangioleiomyomatosis market includes the following segments:
Geographically, the lymphangioleiomyomatosis market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America is projected to hold the largest market share in the forecast period. The dominance is attributed to factors such as high healthcare spending, a high rate of adoption of technologies, a rise in the prevalence of lifestyle-related disorders, and a promising pipeline. Further, the ease of availability of lymphangioleiomyomatosis therapies, rise in R&D concerning lymphangioleiomyomatosis, and the availability of reimbursements are also contributing towards the regional growth.
According to the U.S. Department of Health and Human Services, the number of women in the U.S. who have been diagnosed with lung disease is increasing.
The European region is anticipated to hold the second-largest market share in the lymphangioleiomyomatosis market after North America on account of rising government spending related to healthcare facilities in the region.
Asia-Pacific is estimated to grow at the fastest rate during the forecast period. Factors such as growth in the incidence of lymphangioleiomyomatosis disorders, lung infections & surgeries, increased menopausal female populations, upsurge in healthcare expenditure, penetration of leading players, budding population, and a rise in disposable income, are projected to propel the growth in the Asia-Pacific region.
Latin America and the Middle East and Africa are estimated to experience scalable heights in the foreseeable future on account of efforts made by the governments of these regions to promote the use of medications and spread the awareness related to health disorders.
The lymphangioleiomyomatosis market is further classified based on region as follows:
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
